logo
Plus   Neg
Share
Email

Altimmune Submits IND Application For AdCOVID Intranasal COVID-19 Vaccine - Quick Facts

Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, said Wednesday that it has submitted an Investigational New Drug or IND application to the U.S. Food and Drug Administration (FDA) to commence a Phase 1 clinical study of its single-dose intranasal COVID-19 vaccine candidate, AdCOVID.

AdCOVID is designed to stimulate a broad immune response including both systemic immunity (neutralizing antibody) and local immunity (mucosal IgA and resident memory T cells) in the nasal cavity and respiratory tract.

Altimmune noted that the single-dose nasal spray offers greater ease and comfort of administration and positions AdCOVID as a differentiated vaccine candidate for adults and children.

According to the company, AdCOVID is capable of stimulating an additional and specialized type of immunity, local nasal mucosal immunity, that is believed to be critical for preventing further transmission of the virus.

"We've made exceptional progress advancing AdCOVID and are on track to begin a Phase 1 clinical study this year, with a data readout anticipated in the first quarter of 2021. While the progress being reported with current vaccines is very encouraging, many in the scientific and medical communities agree that there is continued need for next-generation vaccines that offer significant enhancements," said Vipin Garg, President and Chief Executive Officer of Altimmune.

Altimmune noted that the FDA, in a recent pre-IND meeting, agreed to the overall Phase 1 study design and patient population, as well as plans for manufacturing and product testing of AdCOVID.

Further, the FDA confirmed that additional nonclinical studies were not required and that the toxicology data previously submitted and reviewed for Altimmune's NasoShield and NasoVAX intranasal vaccine candidates support the clinical development of AdCOVID.

No additional toxicology studies are required before the start of the Phase 1 trial.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
South Korea's Hyundai Motor Co. announced its decision to suspend production at its Asan plant for two days starting on Monday due to a chip shortage amid the pandemic crisis, Reuters reported. The company is experiencing trouble in supply conditions for semiconductor parts for powertrain control units. The Asan factory manufactures 300,000 vehicles, including the Sonata and Grandeur sedans, each The U.S. Department of Health and Human Services is set to expand its Health Center COVID-19 Vaccine Program to include all HRSA-funded health centers. This will increase the total number of health centers that have been invited to join the program to 1,470 nationwide from the earlier 950. McDonald's Corp. is planning to hire 25,000 workers in its restaurants across Texas in April, reports said. In a three-day event from April 13 to 15, the fast-food chain is expected to hire for crew and management positions. During these hiring days, participating McDonald's restaurants in the state will be accepting applications and interviewing job seekers.
Follow RTT